We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Are the Key Projections for the CAGR of the Cardiotonic Agents Market Size From 2025 to 2034?

The market size of cardiotonic agents has seen swift expansion in the recent past. The market is projected to increase from $2.78 billion in 2024 to $3.14 billion in 2025, boasting a compound annual growth rate (CAGR) of 12.9%. Factors contributing to this growth during the historic period include the rising number of heart failure cases, an aging population, increased cases of coronary artery disease, growing prevalence of inactive lifestyles, as well as an increasing burden of hypertension and diabetes.

In the coming years, the cardiotonic agents market is projected to experience significant growth. By 2029, it’s anticipated to reach $5.06 billion, with a compound annual growth rate (CAGR) of 12.6%. Factors such as increased cardiovascular mortality rates, expanding clinical tests for enhanced cardiotonic formulations, increased public-private collaboration in cardiovascular drug production, growing hospital admissions resulting from cardiac issues, and a rising trend for personalized cardiovascular treatment contribute to growth in the forecast period. Key trends predicted during this period include the development of peptide-based cardiotonic agents and dual-mechanism drugs, the application of pharmacogenomics, innovative injectable depot formulations, and combination therapies innovation.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

Which Primay Drivers Are Accelerating Growth in the Cardiotonic Agents Market?

The anticipated surge in cardiovascular disorders is predicted to significantly boost the cardiotonic agents market moving forward. Cardiovascular diseases (CVDs) encompass a variety of disorders influencing the heart and blood vessels, such as coronary artery disease, heart failure, arrhythmias, and stroke. The increase in CVDs is predominantly due to unhealthful diets loaded with saturated fats, trans fats, salt, and added sugars, resulting in obesity, hypertension, and high cholesterol levels. Cardiotonic agents bolster the efficacy and the contraction power of the heart muscle, thereby enhancing blood circulation and alleviating symptoms in multiple cardiovascular conditions. For instance, as per the data from the Australian Institute of Health and Welfare in December 2023, a government agency based in Australia, medically verified fatalities due to coronary heart disease (CHD) in Australia rose from 14,100 in 2021 to 14,900 in 2022. As such, the escalating prevalence of cardiovascular disorders is stimulating the expansion of the cardiotonic agents market.

Which Primary Segments of the Cardiotonic Agents Market Are Driving Growth and Industry Transformations?

The cardiotonic agents market covered in this report is segmented –

1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Dosage Form: Tablet, Solution, Other Dosage Forms

4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C

2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone

3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine

4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine

5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol

Request customized data on this market:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

Which Regions Are Key Players in the Growth of the Cardiotonic Agents Market?

North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Cardiotonic Agents Industry Dynamics?

The primary players in the cardiotonic agents market are directing their efforts towards the development of novel products like short-term inotropic drugs, designed to boost heart function during acute heart failure and cardiogenic shock. These short-term inotropic medicines serve to augment the heart’s contractile ability in the short run, thereby enhancing cardiac output. For example, Dobutamine Injection, USP, in a 250 mg/20 mL vial, was introduced by UK-based pharmaceutical firm Hikma Pharmaceuticals plc in June 2023. This injection is intended for the short-term inotropic aid in adults suffering from cardiac decompensation due to diminished heart contractility, which is commonly a consequence of heart disease or post-cardiac surgery. It operates by triggering beta-1 receptors, thereby increasing the contractility of the heart muscle and cardiac output swiftly (1–2 minutes). This injection is typically given in a hospital under close supervision and is administered intravenously.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report

What Parameters Are Used to Define the Cardiotonic Agents Market?

Cardiotonic agents are a class of drugs that improve the efficiency and contraction of the heart muscle, improving its ability to pump blood. These agents are used to treat heart failure and certain arrhythmias by increasing cardiac output and improving circulation.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/customise?id=24184&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model